Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models

Area of Science:

• Hematology and Oncology
• Immunology
• Cancer Biology

Background:

• Lymphomas, particularly B cell Non-Hodgkin lymphomas (B-NHL), are frequent blood cancers originating from germinal center (GC) B cells.
• GCs are critical for B cell maturation, but genomic instability during somatic hypermutation (SHM) and class-switch recombination (CSR) increases cancer risk.
• Follicular Lymphoma (FL) and GCB diffuse large B cell lymphomas (GCB-DLBCL) frequently arise from GC B cell differentiation errors.

Purpose of the Study:

• To review genetically engineered mouse models (GEMMs) that recapitulate lymphoma-associated alterations in FL and GCB-DLBCL.
• To highlight how GEMMs advance our understanding of GC B cell transformation and lymphomagenesis.
• To underscore the importance of GEMMs in studying disease progression and testing targeted therapies.

Main Methods:

• Review of existing literature on genetically engineered mouse models for FL and GCB-DLBCL.
• Analysis of how these models mimic specific genetic and epigenetic alterations found in human lymphomas.
• Discussion of the utility of GEMMs in studying the functional consequences of these alterations in vivo.

Main Results:

• GEMMs have been instrumental in identifying oncogenes and tumor suppressors involved in FL and DLBCL pathogenesis.
• These models accurately replicate in vivo lymphoma-specific mutations, allowing interrogation of their oncogenic functions.
• GEMMs provide insights into the molecular mechanisms driving GC B cell transformation and lymphoma development.

Conclusions:

• Genetically engineered mouse models are essential tools for dissecting the complex molecular events underlying FL and GCB-DLBCL.
• GEMMs facilitate the study of B cell transformation within the GC ecosystem and disease progression.
• These models are crucial for pre-clinical evaluation of novel targeted therapies for these lymphoid malignancies.